|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Mar 31, 2012
|
Q4 FY2011
As of Mar 31, 2011
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Restricted cash and cash equivalents - Asbestos | |||||||||||||||||
| Restricted cash and cash equivalents | |||||||||||||||||
| Restricted short-term investments — Asbestos | |||||||||||||||||
| Accounts and other receivables, net | |||||||||||||||||
| Inventories | |||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||
| Assets held for sale | |||||||||||||||||
| Insurance receivable - Asbestos | |||||||||||||||||
| Workers’ compensation - Asbestos | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||
| Finance lease right-of-use assets | |||||||||||||||||
| Goodwill | |||||||||||||||||
| Intangible assets, net | |||||||||||||||||
| Restricted long-term investments - Asbestos | |||||||||||||||||
| Insurance receivable - Asbestos | |||||||||||||||||
| Workers’ compensation - Asbestos | |||||||||||||||||
| Deferred income taxes | |||||||||||||||||
| Deferred income taxes — Asbestos | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities and Shareholders’ Equity | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable and accrued liabilities | |||||||||||||||||
| Accrued payroll and employee benefits | |||||||||||||||||
| Operating lease liabilities | |||||||||||||||||
| Finance lease liabilities | |||||||||||||||||
| Long-term debt, current portion | |||||||||||||||||
| Accrued product warranties | |||||||||||||||||
| Income taxes payable | |||||||||||||||||
| Asbestos liability | |||||||||||||||||
| Workers’ compensation - Asbestos | |||||||||||||||||
| Other liabilities | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Long-term debt | |||||||||||||||||
| Deferred income taxes | |||||||||||||||||
| Operating lease liabilities | |||||||||||||||||
| Finance lease liabilities | |||||||||||||||||
| Accrued product warranties | |||||||||||||||||
| Income taxes payable | |||||||||||||||||
| Asbestos liability | |||||||||||||||||
| Workers’ compensation - Asbestos | |||||||||||||||||
| Other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Shareholders’ equity: | |||||||||||||||||
| Common stock, Euro 0.59 par value, 2.0 billion shares authorized; 580,354,409 shares issued and outstanding at June 30, 2026 and 580,174,308 shares issued and outstanding at March 31, 2026 | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Retained earnings | |||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||
| Total shareholders’ equity | |||||||||||||||||
| Total liabilities and shareholders’ equity | |||||||||||||||||
Loading...